Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

Clinical Tools for Pediatric CVD Risk Reduction and Asthma Treat

What are effective strategies and clinical decision support tools that can maximize pediatric care providers’ adoption of evidence-based recommendations for assessment and treatment of cardiovascular risk factors and/or asthma? • Clinical recommendations and associated implementation tools are often incorporated into electronic medical records (EMRs). Currently there is no standard EMR format and therefore it is difficult ...more »

Voting

0 net votes
10 up votes
10 down votes
Active
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

Developing Research to Address the Critical Problem of Nonadherence to Effective Treatments

A large gap in healthcare is nonadherence to proven effective treatments. One important area for reducing morbidity, mortality and cost for patients with chronic diseases that require frequent home, non-healthcare assisted, administration of treatment is the promotion of adherence to treatment recommendations.

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

Translation of scientific information into clinical and public health asthma and allergies practices and programs

More evidence-based, scientifically proven interventions to ensure that scientific information is translated into clinical and public health practices and programs to reduce the burden of asthma and allergies on individuals, families and society

Voting

1 net vote
1 up votes
0 down votes
Active
(@robert.paine)

Goal 3: Advance Translational Research

Understanding heterogeneity in ARDS

ARDS is a syndrome, yet we treat it as though it was a single clinical disease. There has been success in improving the process of care for patients with ARDS, but no real progress on address the underlying process. For successful therapies to influence the disease process, we need to be able to distinguish the mechanisms active in individual patients and so that we can design and test interventions targeting the specific ...more »

Voting

0 net votes
3 up votes
3 down votes
Active
(@roy.wallen)

Goal 3: Advance Translational Research

Early prediction of cardiovascular disease by primary-care assessment

Tools for early assessment of cardiovascular disease have become available but not adopted in primary-care settings. Increased arterial stiffness is a well-known marker for advanced cardiovascular disease (CVD) and has been shown to be an independent predictor of cardiovascular mortality. In addition, arterial pulse wave velocity (PWV) has been readily accepted as a measure of arterial stiffness. Despite significant ...more »

Voting

5 net votes
8 up votes
3 down votes
Active
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

It’s not just about adults…

Given the lack of outcomes data in the pediatric population, there is a need to develop a repository of data, including integrated electronic clinical data (outpatient, inpatient, laboratory, imaging, prescription), on all CVD risk factors (e.g. hypertension, dyslipidemia) in children. One approach is to start with leveraging health care systems that have existent electronic clinical data, infrastructure in place for ...more »

Voting

21 net votes
32 up votes
11 down votes
Active
(@jlombard)

Goal 3: Advance Translational Research

Direct Upregulation of Antioxidant Defenses as a Therapeutic Strategy

Clinical trials involving administration of antioxidants such as vitamin C or vitamin E as therapeutic strategies for cardiovascular diseases associated with oxidant stress have proven to be surprisingly disappointing. A particularly attractive alternative approach is direct upregulation of endogenous antioxidant defenses such as NRF2 via dietary approaches. NRF2 is a master antioxidant and cell protective transcription ...more »

Voting

-5 net votes
2 up votes
7 down votes
Active
(@jnoel0)

Goal 3: Advance Translational Research

DEVELOPMENT OF BIOMARKERS FOR SLEEP INSUFFICIENCY, CIRCADIAN DISRUPTION AND SLEEP DISORDERS

There is an urgent need to develop quantifiable biomarkers for acute sleep loss, chronic sleep insufficiency, circadian disruption and sleep disorders such as obstructive sleep apnea. These problems are highly prevalent but currently we do not have biomarkers to use for case identification, prognosis, or assessing response to therapy. There are currently small studies that indicate the feasibility. A recent workshop ...more »

Voting

179 net votes
240 up votes
61 down votes
Active
(@jantin)

Goal 3: Advance Translational Research

Can SYK or BTK inhibition ameliorate autoimmune hemolytic anemia after stem cell transplantation

Experimental mouse models of ITP and AIHA are dependent on FcgR-signaling, which in turn depends on Syk kinase activity for activation of phagocytes. A significant and refractory complication of stem cell transplantation is immune hemolytic anemia. This can be either autoimmune or alloimmune. In either case it is likely that clearance of RBC and RBC progenitors is dependent on extravascular mechanisms involving activation ...more »

Voting

23 net votes
52 up votes
29 down votes
Active
(@amy.sobota)

Goal 3: Advance Translational Research

Implementation Science to Improve Care in Sickle Cell Disease

There are approximately 100,000 individuals living with sickle cell disease in the US, however study after study has shown that many lack access to the few existing evidence based interventions such as hydroxyurea. We need to investigate novel ways to increase acess to hematology care and disease modifying therapies.

Voting

12 net votes
14 up votes
2 down votes
Active
(@wangq2)

Goal 3: Advance Translational Research

Genetics and Genomics of Heart Disease

Identification of new genetic/genomic variants and risk genes often opens a new window to explore the fundamental molecular mechanisms underlying a disease and to develop new methods and strategies for diagnosis and treatment. Existing genomic variants and/or mutations explain only 10% to 20% heritability of common heart diseases. Much remains to be done in this important area. However, most genetic projects are discovery-driven ...more »

Voting

-1 net votes
5 up votes
6 down votes
Active